iStock/Tippapatt
MTD (Medical Technology and Devices), a provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations with the pen needle and BGMs portfolio from Ypsomed - a developer and manufacturer of injection and infusion systems for self-medication for 40 years.
The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary conditions.
